Menicon Co Ltd (Menicon) designs, manufactures, imports, exports and sells contact lenses, medical goods, medical instruments, and medical supplies. The company operates factories in Gifu Prefecture, Japan and overseas in Malaysia, Singapore, China, and Europe. It sells its products through wholesale, retail stores, and a monthly membership system called Mels Plan. Globally, Menicon sells private-brand lenses to large retail chains in Europe and America, distributes lenses to eye clinics in Asia, and ships products through logistics hubs in Japan and Germany.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Menicon has undertaken several R&D initiatives, including the development of silicone hydrogel daily disposable lenses, enhancement of production capacity at the Kakamigahara and Malaysia plants, development of orthokeratology and myopia-control lenses, and enhancement of lens-care products. The company is also working on applications for its self-assembling peptide gel technology and has obtained medical-device approval for a bone-filling material. Additionally, Menicon Bloom Night, a myopia-control orthokeratology lens, holds CE-mark certification. The R&D units of the company include the General Research Institute, Techno Station, and the Clinical Research Institute. The General Research Institute focuses on developing contact lens materials and products. Techno Station is responsible for developing production technologies, while the Clinical Research Institute evaluates the safety and efficacy of products. Other units include the Menicon R&D Center, Techno Station, Menicon Nect Development Center, and various satellite research facilities, each focusing on different aspects of contact lens and care product development. The pipeline products include silicone hydrogel daily disposable lenses, orthokeratology lenses, and myopia-control lenses. In FY2026, the company spent JPY5,543 million on its R&D activities, which as a percentage of revenue stood at 4.4%.